The Regeneron Genetics Center (RGC) has built one of the world’s most comprehensive genetics databases, pairing the sequenced exomes and de-identified electronic health records of more than 400,000 people so far. Building upon our strengths in mouse genetics and genetics-driven drug discovery, this information will allow us to elucidate, on a large scale, genetic factors that cause or influence a range of human diseases. We believe that this knowledge can advance basic science around the world, provide clinically valuable insights to physicians and patients and ultimately make drug development faster and more precise.

Our team conducts gene sequencing projects, functional biology, disease modeling and the translation of genetics findings into Regeneron’s preclinical and clinical pipelines. We are using our unique database and state-of-the-art analysis capabilities to identify new drug targets and therapeutic indications, to validate our existing programs and to build better-informed clinical trials. Our explorations include Mendelian and family frameworks, large-scale population genetics (both common and rare variants) and gene-gene interactions.

exomes sequenced to date


We are honored to have important leaders in the genetics community as members of our Scientific Advisory Board:

Richard Lifton, MD, PhD
President of the Rockefeller University

Wendy K. Chung, MD, PhD
Herbert Irving Associate Professor of Pediatrics at the Columbia University Medical Center

Peter Donnelly, PhD
Professor of Statistical Science and Director of the Wellcome Trust Centre for Human Genetics

Tim Hunkapiller, PhD
President of Discovery Biosciences Corporation

Sekar Kathiresan, MD
Director of Preventive Cardiology at Massachusetts General Hospital, Associate Member in the Broad Institute's Program in Medical and Population Genetics and Associate Professor of Medicine at Harvard Medical School

James R. Lupski, MD, PhD, DSc (hon)
Cullen Professor Molecular and Human Genetics at the Baylor College of Medicine

Elaine R. Mardis, PhD
Robert E. and Louise F. Dunn Distinguished Professor of Medicine and Co-Director at the McDonnell Genome Institute at the Washington University School of Medicine


Our collaborations bolster our deep knowledge of genetics and sequencing capabilities with patient-consented genetic samples and de-identified clinical data.

These projects marry healthcare provider and academic expertise with translational follow up, thus making data actionable and contributing to the development of new medicines. We work hand-in-hand with our partners to analyze data, prepare high-profile, peer-reviewed publications and in some cases enable physicians to return results to their patients to immediately improve diagnosis and treatment.

We are always open to new collaborations with leading healthcare providers, academic researchers and government researchers who can contribute patient-consented samples with well-annotated and de-identified clinical data. For more information, please contact

Accelerating drug discovery
and development with genetics research